ERBB2 and breast cancer: While derived from a single-arm, single-center phase II trial, long-term outcomes of TUXEDO-1 support the role of ADCs as systemic therapy for active BM and need to be discussed in the light of results of other studies evaluating systemic therapy in HER2-positive BC BM.